Related Experiment Video
Updated: Nov 4, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative
Ren-Bo Ding1,2, Ping Chen1,2,3, Barani Kumar Rajendran1,2
1Cancer Centre, Faculty of Health Sciences, University of Macau, Macau SAR, China.
Abstract:
Nasopharyngeal carcinoma (NPC) is a malignant head and neck cancer type with high morbidity in Southeast Asia, however the pathogenic mechanism of this disease is poorly understood. Using integrative pharmacogenomics, we find that NPC subtypes maintain distinct molecular features, drug responsiveness, and graded radiation sensitivity. The epithelial carcinoma (EC) subtype is characterized by activations of microtubule polymerization and defective mitotic spindle checkpoint related genes, whereas sarcomatoid carcinoma (SC) and mixed sarcomatoid-epithelial carcinoma (MSEC) subtypes exhibit enriched epithelial-mesenchymal transition (EMT) and invasion promoting genes, which are well correlated with their morphological features. Furthermore, patient-derived organoid (PDO)-based drug test identifies potential subtype-specific treatment regimens, in that SC and MSEC subtypes are sensitive to microtubule inhibitors, whereas EC subtype is more responsive to EGFR inhibitors, which is synergistically enhanced by combining with radiotherapy. Through combinational chemoradiotherapy (CRT) screening, effective CRT regimens are also suggested for patients showing less sensitivity to radiation. Altogether, our study provides an example of applying integrative pharmacogenomics to establish a personalized precision oncology for NPC subtype-guided therapies.
Insights
This study reveals distinct molecular features and drug responses in nasopharyngeal carcinoma (NPC) subtypes. Personalized treatments targeting specific NPC molecular profiles improve therapeutic outcomes.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Nasopharyngeal carcinoma (NPC) is a prevalent head and neck cancer with poorly understood mechanisms.
- Southeast Asia experiences high NPC morbidity, necessitating research into its pathogenesis.
Purpose of the Study:
- To elucidate the pathogenic mechanisms of NPC subtypes using integrative pharmacogenomics.
- To identify subtype-specific treatment strategies for nasopharyngeal carcinoma.
Main Methods:
- Integrative pharmacogenomics analysis of NPC subtypes.
- Patient-derived organoid (PDO) drug sensitivity testing.
- Combinational chemoradiotherapy (CRT) screening.
Main Results:
- NPC subtypes (epithelial carcinoma, sarcomatoid carcinoma, mixed) display distinct molecular profiles and gene expressions.
- Sarcomatoid and mixed subtypes are sensitive to microtubule inhibitors; epithelial subtype responds to EGFR inhibitors.
- Combined therapies, including chemoradiotherapy, show potential for enhanced efficacy in specific NPC subtypes.
Conclusions:
- Integrative pharmacogenomics enables the classification of NPC into distinct subtypes with unique therapeutic vulnerabilities.
- This study supports the development of personalized precision oncology for NPC, guided by subtype-specific molecular characteristics and drug responsiveness.
